SEC Form 4 · accession 0001209191-15-059967
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Jul 2, 2015
Accepted (ET)
Jul 7, 2015 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2015 | M | 2,291 | $73.51 | A | 102,853 | D | |
| Common StockF2,F3 | Jul 2, 2015 | S | 394 | $126.69 | D | 102,459 | D | |
| Common StockF3,F4 | Jul 2, 2015 | S | 500 | $128.12 | D | 101,959 | D | |
| Common Stock | Jul 2, 2015 | S | 100 | $129.54 | D | 101,859 | D | |
| Common StockF3,F5 | Jul 2, 2015 | S | 1,297 | $130.63 | D | 100,562 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $73.51 | Jul 2, 2015 | M | 2,291 | D | — | Jan 1, 2024 | Common Stock | 2,291 | 41,253 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $126.69 (range $126.10 to $126.97).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $128.12 (range $127.81 to $128.47).
- F5Open market sales reported on this line occurred at a weighted average price of $130.63 (range $130.58 to $130.68).
- F6The option vests in 16 quarterly installments from 01/02/2014.